Analex Awarded $9.4 Million to Provide Engineering & Scientific Support to NASA
Tuesday May 13, 8:50 am ET
ALEXANDRIA, Va., May 13 /PRNewswire-FirstCall/ -- Analex Corporation (Amex: NLX - News) announced that it has been awarded approximately $9.4 million to provide support services to NASA. The work performed under this contract consists largely of software engineering, electrical and mechanical systems design and development, design engineering and analysis, communication technology support and general project support, and will be provided primarily by Analex professional staff in the Cleveland, Ohio area.
This new funding represents the exercise of an additional option year under a subcontract to provide engineering and scientific support to the NASA Glenn Research Center under the Glenn Engineering and Scientific Support prime contract held by QSS Group, Inc. Following the completion of this portion of the subcontract in April 2004, there will be one remaining two-year option, with a potential value of approximately $18 million.
Analex's President and Chief Executive Officer, Sterling Phillips, said, "We are gratified that the quality of work Analex has performed for the NASA Glenn Research Center has met or exceeded the expectations of QSS Group and NASA. We are committed to delivering excellent support for the remaining three years of the contract."
Analex specializes in providing intelligence, systems engineering and biodefense services in support of our nation's security. Analex focuses on developing innovative technical approaches for the intelligence community, analyzing and supporting defense systems, designing, developing and testing aerospace systems and developing medical defenses and treatments for infectious agents used in biological warfare and terrorism. The company's stock trades on the American Stock Exchange under the symbol NLX. The company can be found on the Internet at www.analex.com. Analex investor relations can be contacted at (703) 329-9400 or via email at amber.gordon@analex.com.
PLEASE NOTE: Except for the historical information contained herein, this press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. These forward-looking statements may be identified by reference to a future period by use of forward-looking terminology such as "anticipate," "expect," "could," "intend," "may" and other words of a similar nature. There are certain important factors and risks that could cause results to differ materially from those anticipated by the statements contained herein. Such factors and risks include business conditions and growth in the medical research, pharmaceutical and government contracting arenas and in the economy in general. Competitive factors include the pressures toward consolidation of small government contracts into larger contracts awarded to major, multi-national corporations; and the Company's ability to continue to recruit and retain highly skilled scientific, technical, managerial and sales/marketing personnel. Other risks may be detailed from time to time in the Company's filings with the Securities and Exchange Commission. Analex undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Analex Corporation
Copyright © 2003 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback
Copyright © 2003 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
